Altretamine and Myelosuppression
Result of checking the interaction of drug Altretamine and disease Myelosuppression for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:The use of altretamine is contraindicated in patients with severe bone marrow suppression. Altretamine induces mild to moderate dose-related myelosuppression. If white blood cell counts fall below 2000/mm3 and/or platelet counts fall below 75,000/mm3 during altretamine therapy, subsequent doses should be withheld at least 14 days and altretamine restarted at 200 mg/m2/day. Clinical monitoring of hematopoietic function is recommended prior to each course of altretamine and the dose should be adjusted as clinically indicated.
- "Product Information. Hexalen Capsules (altretamine)." US Bioscience, West Conshohoken, PA.